CD14+CD16+单核细胞参与达雷妥尤单抗介导的骨髓瘤细胞杀伤及抗CD47治疗策略
本研究建立自体离体方法,聚焦单核细胞在抗CD38单抗(达雷妥尤单抗,DARA)杀伤多发性骨髓瘤(MM)细胞中的作用。在29例MM患者骨髓样本中发现,单核细胞(CD14+)与MM细胞(CD138+)比值影响DARA反应,DARA暴露后形成CD138+CD14+双阳性(DP)群体且与杀伤定量相关,该效应依赖CD14+CD16+单核细胞亚群和高CD16表达。中和CD47/SIRPα轴的mAb可增强DARA介导的杀伤,且仅在高CD14+:CD138+比值、显著DP群体及CD16表达相关时观察到。
要点
- 骨髓单核细胞与MM细胞比值影响DARA杀伤效果
- CD14+CD16+单核细胞亚群及高CD16表达是DARA杀伤所必需
- 抗CD47 mAb可增强DARA杀伤,支持联合策略
核心结论
- CD16+单核细胞在DARA抗MM杀伤中起关键作用,为抗CD47 mAb联合抗CD38 mAb提供依据。
研究设计与样本
- 研究采用自体离体方法,纳入29例多发性骨髓瘤患者的骨髓样本。
主要发现
- 在29例MM患者骨髓样本中,单核细胞(CD14+)与MM细胞(CD138+)比值影响DARA反应。
- 骨髓样本暴露于DARA后形成CD138+CD14+双阳性(DP)群体,且与抗MM细胞杀伤定量相关。
- 上述效应依赖CD14+CD16+单核细胞亚群的存在及高CD16表达水平。
- 加入中和CD47/SIRPα轴的mAb可增强DARA介导的杀伤。
- 该增强效应仅在高CD14+:CD138+比值、显著DP群体且与CD16表达相关时观察到。
临床怎么用
- 可依据骨髓单核细胞与MM细胞比值及CD16+单核细胞状态评估DARA反应潜力。
- 抗CD47 mAb联合抗CD38单抗的策略值得在适宜患者中测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A deep elucidation of the mechanisms of action of anti-CD38 monoclonal antibodies (mAbs), such as daratumumab (DARA), is required to identify patients with multiple myeloma (MM) who are more responsive to this treatment. In the present study, an autologous ex vivo approach was established, focussing on the role of the monocytes in the anti CD38-mediated killing of MM cells. In bone marrow (BM) samples from 29 patients with MM, we found that the ratio between monocytes (CD14+ ) and MM cells (CD138+ ) influences the response to DARA. Further, the exposure of the BM samples to DARA is followed by the formation of a CD138+ CD14+ double-positive (DP) population, that quantitatively correlates with the anti-MM cells killing. These effects were dependent on the presence of a CD14+ CD16+ monocyte subset and on high CD16 expression levels. Lastly, the addition of a mAb neutralising the CD47/signal-regulatory protein α (SIRPα) axis was able to increase the killing mediated by DARA. The effects were observed only in coincidence with high CD14+ :CD138+ ratio, with a significant presence of the DP population and were correlated with CD16 expression. In conclusion, the present study underlines the critical role of the CD16+ monocytes in DARA anti-MM killing effects and gives a rationale to test the combination of an anti-CD47 mAb with anti-CD38 mAbs.
引用
- Storti P, Vescovini R, Costa F, et al. CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy. Br J Haematol. 2020. PMID: 32162328. doi:10.1111/bjh.16548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。